Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): Clinical rationale and design

Contemporary Clinical Trials

Volumn 37, Issue 2, 2014, Pages 200-208

  Pelton, Gregory H ^a,b   Andrews, Howard ^a,b   Roose, Steven P ^a,b   Marcus, Sue M ^b,c   D'Antonio, Kristina ^a   Husn, Hala ^d   Petrella, Jeffrey R ^d   Zannas, Anthony S ^d   Doraiswamy, P Murali ^d,e   Devanand, D P ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c Department of Medicine   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Alzheimer's disease; Cognitive impairment; Depression; Donepezil; Memory decline; Randomized clinical trial

Indexed keywords

ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E4; DONEPEZIL; PLACEBO; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEPRESSION; FEMALE; HAMILTON SCALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PILOT STUDY; SCORING SYSTEM; TREATMENT OUTCOME; VERY ELDERLY; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; DAILY LIFE ACTIVITY; DEPRESSIVE DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; RESEARCH DESIGN;

EID: 84892657466     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.11.015     Document Type: Article

References (32)

1. Steffens D.C., Otey E., Alexopoulos G.S., Butters M.A., Cuthbert B., Ganguli M., et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry Feb 2006, 63(2):130-138. [http://archpsyc.jamanetwork.com/article.aspxαarticleid=209350 (9/20/2013)]. 10.1001/archpsyc.63.2.130.
2. Devanand D.P., Sano M., Tang M.X., Taylor S., Gurland B.J., Wilder D., et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry Feb 1996, 53(2):175-182. [http://archpsyc.jamanetwork.com/article.aspxαarticleid=497539 (9/20/2013)]. 10.1001/archpsyc.1996.01830020093011.
3. Byers A.L., Covinsky K.E., Barnes D.E., Yaffe K. Dysthymia and depression increase risk of dementia and mortality among older veterans. Am J Geriatr Psychiatry Aug 2012, 20(8):664-672. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229643/ (9/20/2013)]. 10.1097/JGP.0b013e31822001c1.
4. Taylor W.D., Wagner H.R., Steffens D.C. Greater depression severity associated with less improvement in depression-associated cognitive deficits in older subjects. Am J Geriatr Psychiatry 2002, 10(5):632-635. [http://www.ncbi.nlm.nih.gov/pubmed/12213698 (9/20/2013) PMID: 12213698].
5. Nebes R.D., Pollock B.G., Houck P.R., Butters M.A., Mulsant B.H., Zmuda M.D., et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res Mar-Apr 2003, 37(2):99-108. [http://www.sciencedirect.com/science/article/pii/S0022395602000857 (9/20/2013)]. 10.1016/S0022-3956(02)00085-7.
6. Salloway S., Ferris S., Kluger A., Goldman R., Griesing T., Kumar D., et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004 Aug, 63(4):651-657. [http://www.neurology.org/content/63/4/651.long (9/20/2013)]. 10.1212/01.WNL.0000134664.80320.92.
7. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med Jun 2005, 352(23):2379-2388. [http://www.nejm.org/doi/full/10.1056/NEJMoa050151 (9/20/2013)]. 10.1056/NEJMoa050151.
8. Devanand D.P., Pelton G.H., Marston K., Camacho Y., Roose S.P., Stern Y., et al. Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 2003, 18:123-130. [9/20/2013]. 10.1002/gps.802/abstract;jsessionid=E2087E96DB3D7DFC7EB6A4D8E9AD2250.d02t04.
9. Reynolds C.F., Butters M.A., Lopez O., Pollock B.G., Dew M.A., Mulsant B.H., et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry Jan 2011, 68(1):51-60. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076045/ (9/20/2013)]. 10.1001/archgenpsychiatry.2010.184.
10. Lu P.H., Edland S.D., Teng E., Tingus K., Petersen R.C., Cummings J.L. Alzheimer's disease cooperative study group. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology Jun 2009, 72(24):2115-2121. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697965/ (9/20/2013)]. 10.1212/WNL.0b013e3181aa52d3.
11. Pelton G.H., Harper O.L., Tabert M.H., Sackeim H.A., Scarmeas N., Roose S.P., et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry Jul 2008, 23(7):670-676. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104294/ (9/20/2013)]. 10.1002/gps.1958.
12. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., et al. Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology Aug 2001, 57(3):489-495. [http://www.neurology.org/content/57/3/489.long (9/20/2013)]. 10.1212/WNL.57.3.489.
13. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Standlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology Jul 1984, 34(7):939-944. [http://www.neurology.org/content/34/7/939.full.pdf+html (9/20/2013)]. 10.1212/WNL.34.7.939.
14. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology Dec 2005, 65(12):1863-1872. [http://www.neurology.org/content/65/12/1863.long (9/20/2013)]. 10.1212/01.wnl.0000187889.17253.b1.
15. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology Feb 1993, 43(2):250-260. [http://www.ncbi.nlm.nih.gov/pubmed/8094895 (9/20/2013) PMID: 8094895].
16. Lund-Manchester-Group Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry Apr 1994, 57:416-418. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1072868/ (9/20/2013) PMCID: PMC1072868].
17. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol Mar 1999, 56(3):303-308. [http://archneur.jamanetwork.com/article.aspxαarticleid=774828 (9/20/2013)]. 10.1001/archneur.56.3.303.
18. Pfeffer R.I., Kurosaki T.T., Harrah C.H., Chance J.M., Filos S. Measurement of functional activities in older adults in the community. J Gerontol May 1982, 37(3):323-329. [http://www.ncbi.nlm.nih.gov/pubmed/7069156 (9/20/2013) PMID: 7069156].
19. Koontz J., Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Demen Sep-Oct 2005, 20(5):295-302. [http://aja.sagepub.com/content/20/5/295.long (9/20/2013)]. 10.1177/153331750502000502.
20. Doty R.L., Perl D.P., Steele J.C., Chen K.M., Pierce J.D., Reyes P., et al. Olfactory dysfunction in three neurodegenerative diseases. Geriatrics Aug 1991, 46(Suppl.1):47-51. [http://www.ncbi.nlm.nih.gov/pubmed/1894145 (9/20/2013) PMID:1894145].
21. Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Rusinek H., et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology Mar 2007, 68(11):828-836. [http://www.neurology.org/content/68/11/828.long (9/20/2013)]. 10.1212/01.wnl.0000256697.20968.d7.
22. Buschke H., Fuld P.A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology Nov 1974, 24(11):1019-1025. [http://www.neurology.org/content/24/11/1019.short (9/20/2013)]. 10.1212/WNL.24.11.1019.
23. Wechsler D. Wechsler memory scale-revised 1987, The Psychological Corporation, San Antonio, TX.
24. Goodglass H., Kaplan E. The assessment of aphasia and related disorders 1983, Lea & Febiger, Philadelphia. 2nd ed.
25. Lezak M. Neuropsychological assessment 1995, Oxford University Press, New York. 3rd ed.
26. Laird N.M. Missing data in longitudinal studies. Stat Med Jan-Feb 1988, 7(1-2):305-315. [9/20/2013]. 10.1002/sim.4780070131/abstract.
27. Gibbons R.D., Hedeker D., Elkin I., Waternaux C., Kraemer H.C., Greenhouse J.B., et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry Sept 1993, 50(9):739-750. [http://archpsyc.jamanetwork.com/article.aspxαarticleid=496334 (9/20/2013)]. 10.1001/archpsyc.1993.01820210073009.
28. Hedeker D., Gibbons MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed May 1996, 49(3):229-252. [http://www.sciencedirect.com/science/article/pii/0169260796017233 (9/20/2013)]. 10.1016/0169-2607(96)01723-3.
29. Kraemer H.C., Wilson G.T., Fairburn C.G., Agras S.W. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry Oct 2002, 59(10):877-883. [http://www.ncbi.nlm.nih.gov/pubmed/12365874 (9/20/2013) PMID: 12365874].
30. Hsieh F.Y. Sample size formulae for intervention studies with the cluster as unit of randomization. Stat Med Nov 1988, 7(11):1195-1201. [http://www.ncbi.nlm.nih.gov/pubmed/3201045 (9/20/2013) PMID: 3201045].
31. Hsieh A. Sample size program for clinical and epidemiologic studies. Am Stat 1991, 45(4):338. [http://www.jstor.org/stable/2684466 (9/20/2013)].
32. Hedeker D., Gibbons R.D., Waternaux C. Sample size estimation for longitudinal designs with attrition:comparing time-related contrasts between two groups. J Educ Behav Stat 1999, 24(1):70-93. [http://www.uic.edu/classes/bstt/bstt513/rrmpow.pdf (9/20/2013)].